Csernansky J G, Csernansky C A, Hollister L E
Experientia. 1985 Nov 15;41(11):1419-21. doi: 10.1007/BF01950013.
3[H]-(-)-Sulpiride and 3[H]-spiperone binding was compared in rat amygdala, nucleus accumbens and striatum, using (+/-)-sulpiride to define specific binding. 3[H]-(-)-Sulpiride bound to twice as many sites in amygdala and nucleus accumbens as 3[H]-spiperone. 3[H]-(-)-Sulpiride binding was directed to these additional sites by using 1 microM spiperone to mask dopaminergic binding. The binding of 3[H]-(-)-sulpiride to these sites was high affinity, reversible, Na+-dependent, but not stereospecific. Metoclopramide, tiapride and antidepressant medications, but not other neuroleptics, ADTN, or serotonin displaced 3[H]-(-)-sulpiride binding to these sites. These data suggest that 3[H]-(-)-sulpiride labels mesolimbic sites other than dopamine receptors which may mediate antidepressant effects.
使用(±)-舒必利来定义特异性结合,比较了3[H]-(-)-舒必利和3[H]-螺哌隆在大鼠杏仁核、伏隔核和纹状体中的结合情况。3[H]-(-)-舒必利在杏仁核和伏隔核中的结合位点数量是3[H]-螺哌隆的两倍。通过使用1微摩尔的螺哌隆来掩盖多巴胺能结合,3[H]-(-)-舒必利的结合指向了这些额外的位点。3[H]-(-)-舒必利与这些位点的结合具有高亲和力、可逆、依赖钠离子,但不具有立体特异性。甲氧氯普胺、硫必利和抗抑郁药物,但不是其他抗精神病药物、ADTN或血清素,可取代3[H]-(-)-舒必利与这些位点的结合。这些数据表明,3[H]-(-)-舒必利标记了除多巴胺受体之外的中脑边缘位点,这些位点可能介导抗抑郁作用。